DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1 clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program that targets aSyn, a protein that has been identified as genetically linked to Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: beta-secretase 1/Tau, a bispecific program targeting the production of amyloid beta and the spreading of Tau. Further, it is developing LF1, a protein to treat neurodegeneration; and DNL788, a small molecule product candidate for the treatment of Alzheimer's disease and ALS. Additionally, the company has various seed program, which are under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., as well as F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, and AbCellera Biologics. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

$51.72  +0.55 (1.08%)
As of 05/13/2021 15:59:59 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/08/2017
Outstanding shares:  121,192,210
Average volume:  428,209
Market cap:   $6,249,882,270
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    24823R105
ISIN:        US24823R1059
Sedol:      BD2B4V0
Valuation   (See tab for details)
PE ratio:   114.14
PB ratio:   5.97
PS ratio:   18.38
Return on equity:   5.23%
Net income %:   17.02%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy